Omni Peptides

Tesamorelin + Ipamorelin Blend

Dhs. 600.00 AED

Sale Sold out

CHOOSE YOUR FORMAT

VIAL

Freeze-dried powder in a sealed glass vial. Reconstitute with bacteriostatic water and administer via syringe. The most versatile and cost-effective research format.

RECONSTITUTION & SYRINGE REQUIRED

CARTRIDGE

Pre-filled and ready to administer. Slides into a reusable pen injector — no measuring or mixing required. Clean, discreet, and consistent across research protocols.

REQUIRES COMPATIBLE PEN INJECTOR

NASAL

Delivered via mucosal absorption — no needles required. A popular choice for research protocols where needle-free administration is preferred.

NEEDLE-FREE — SPRAY & GO

PEN

An all-in-one auto-injector with the cartridge pre-loaded. Dial, click, and administer. Optimal for high-frequency research protocols requiring precise, repeatable dosing.

DIAL, CLICK & INJECT — NO PREP

Vials are freeze-dried (lyophilised) powder — kept refrigerated unopened, they remain stable for up to 2 years.

Cartridges, nasal sprays, and pens arrive pre-filled as liquid, must be kept refrigerated at all times, and carry a Beyond Use Date — typically 4–8 weeks from receipt. Please refer to the BUD on the label.

Size 13 mg (10+3)

Lyophilised & sealed vials

Independent COA · ≥99% purity

Cold-chain dispatch · same day Dubai

Discreet · unbranded outer packaging

Tesamorelin + Ipamorelin Blend (also called Tesa/Ipa or Tesamorelin/Ipamorelin stack) is a synthetic peptide combination pairing Tesamorelin (a stabilized GHRH analog) with Ipamorelin (a selective ghrelin-receptor / GHS-R1a agonist). This research formulation is studied for synergistic stimulation of endogenous pulsatile growth hormone (GH) release and subsequent IGF-1 elevation, while aiming to keep off-target hormonal effects relatively low.

Tesamorelin provides prolonged GHRH-receptor activation and is particularly associated in research with visceral-fat and metabolic endpoints. Ipamorelin adds selective GHS-R1a stimulation that can increase GH pulse amplitude/frequency with minimal effects on cortisol and prolactin in preclinical models. Together they are used to investigate combined GHRH + GHS signaling, body-composition change, tissue repair, and age-related GH-axis decline. As a research-grade compound, this blend is intended exclusively for in vitro and animal studies.

Research Applications

Combination studies examine supra-additive pulsatile GH output versus either peptide alone, while preserving more physiological pulse architecture than long-acting DAC-modified GHRH analogs.

Tesamorelin’s documented effects on visceral adipose tissue are studied alongside Ipamorelin’s anabolic and lipolytic support, with interest in fat-mass reduction and lean-mass preservation.

The blend is used in models of sarcopenia, cachexia, connective-tissue injury, and post-catabolic recovery via elevated GH/IGF-1 signaling.

Research explores insulin sensitivity, lipid profiles, and GH-axis restoration in aging or metabolically disrupted models.

Ipamorelin’s relatively clean GHS-R1a activity is often chosen to limit cortisol/prolactin rise compared with older GHRPs, while Tesamorelin supplies the GHRH-side stimulus.

Storage & Handling

Lyophilised vials are stable at −20°C for up to 2 years unopened. Once reconstituted, refrigerate at 2–8°C and use within 28 days. Avoid repeated freeze-thaw cycles.

Beyond Use Date

Pre-filled formats (cartridge, pen, nasal) carry a beyond-use date of typically 4–8 weeks from receipt. ≥98% purity by HPLC. For in vitro and preclinical research use only — not for human or veterinary use.

— About this compound

A synthetic pentadecapeptide.

VIAL ANATOMY

LYOPHILISED VIAL

Flip-off cap

Tamper-evident seal

Rubber stopper

Bacteriostatic-water compatible

Batch-labelled body

Lot & expiry printed

USP Type I glass

Borosilicate, sealed

Tesamorelin + Ipamorelin Blend

13 mg (10+3)

DUBAI PEPTIDES

RESEARCH USE ONLY

BLACK RESEARCH SERIES

Research Applications

Where researchers apply it.

Combination studies examine supra-additive pulsatile GH output versus either peptide alone, while preserving more physiological pulse architecture than long-acting DAC-modified GHRH analogs.

Tesamorelin’s documented effects on visceral adipose tissue are studied alongside Ipamorelin’s anabolic and lipolytic support, with interest in fat-mass reduction and lean-mass preservation.

The blend is used in models of sarcopenia, cachexia, connective-tissue injury, and post-catabolic recovery via elevated GH/IGF-1 signaling.

Research explores insulin sensitivity, lipid profiles, and GH-axis restoration in aging or metabolically disrupted models.

Ipamorelin’s relatively clean GHS-R1a activity is often chosen to limit cortisol/prolactin rise compared with older GHRPs, while Tesamorelin supplies the GHRH-side stimulus.

— Verified & Documented

Every vial is backed by a Certificate of Analysis.

Each lot is independently characterised by HPLC and mass spectrometry, with identity, mass and purity documented per batch and available on request.

Additional quality-control testing, including sterility, endotoxin and heavy metals, is conducted periodically across our product range.

>99%

HPLC Purity

Identity Confirmed

Certificate of Analysis

TESAMORELIN + IPAMORELIN BLEND · QC RELEASE

PASS

IdentityConfirmed

Mass—

Purity>99%

AppearanceWhite Lyophilised

LabJanoshik Analytical (Independant)

Date